Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 16/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247796 | 1.00 | CA2 (0.55) | CA2CA1FFAR1CYP2C9CYP2B6 | |
| SCHEMBL12056274 | 0.84 | CA2 (0.65) | CA2CA1FFAR1CYP2C9CYP2B6 | |
| SCHEMBL18728166 | 0.81 | FFAR1 (0.51) | CA2FFAR1 | |
| SCHEMBL27823267 | 0.80 | CA2 (0.54) | CA2CA1FFAR1CYP2C9CYP2B6 | |
| SCHEMBL1117923 | 0.79 | CA2 (0.53) | CA2CA1FFAR1CYP2C9CYP2B6 | |
| SCHEMBL13646367 | 0.79 | CA2 (0.53) | CA2CA1FFAR1CYP2C9CYP2B6 | |
| SCHEMBL9375647 | 0.79 | CA2 (0.58) | CA2CA1FFAR1CYP2C9CYP2B6 | |
| SCHEMBL17272320 | 0.77 | CA2 (0.33) | CA2FFAR1 | |
| SCHEMBL27816758 | 0.74 | CA2 (0.70) | CA2CA1FFAR1 | |
| SCHEMBL1044755 | 0.74 | CA2 (0.53) | CA2CA1FFAR1CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182141-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-16 | — | — | US | disclosed |
| US-20090182141-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-16 | — | — | US | disclosed |
| US-20090182141-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-16 | — | — | US | disclosed |
| WO-2009089210-A1 | PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N. V. (BE) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182141-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | STS, SULT2A1, SULT1A1 | CA2 1188/4885CA1 404/4885FFAR1 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.